Orange Grove Bio’s Chief Executive Officer and Co-Founder, Marc Appel was an entrepreneur-in-residence at Yale University. In this role, Marc drove the initiative that propelled university intellectual property into the hands of startups to further fuel the New Haven innovation ecosystem.
Over the years, Marc became an integral part of Yale’s Blavatnik Fund for Innovation, resulting in numerous startups. Recognizing a gap in the research and commercialization process existed beyond Yale and New Haven, Marc, sought to launch a much greater effort. Thus, Orange Grove Bio was born. Today, Orange Grove Bio is headquartered in Cincinnati, Ohio, and places senior personnel in many cities across the country to remain close to innovative partners.
Our mission is to work to bring forward more treatments to treat patients and cure disease.
Orange Grove Bio’s mission is to positively transform the quality of life of patients with cancer, autoimmune, and inflammatory diseases, by expediting the development of new medical breakthroughs.
We strive to foster a more patient-centric approach to drug development and curative therapies through a collaborative ecosystem that bridges early-stage research and pharmaceutical companies.
We are committed to serving as a notable partner to research institutions and pharmaceutical companies, building a diverse, innovative entrepreneurial ecosystem to create additional opportunities, and cultivating the next generation of biotech leaders.